Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Liftoff for the Biotech Launch Pad

    September 20, 2023

    Five things: A biotech IPO, Shannon O’Brien suspension, life sciences philanthropy report

    September 19, 2023

    Machine learning biotech raises $273 million in rare successful late-stage round

    September 15, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Liftoff for the Biotech Launch Pad

      September 20, 2023

      Five things: A biotech IPO, Shannon O’Brien suspension, life sciences philanthropy report

      September 19, 2023

      Machine learning biotech raises $273 million in rare successful late-stage round

      September 15, 2023

      Discover the synergy between biotech, medtech and digital health in Ghent, a European technology capital

      September 14, 2023

      Here are five biotech companies in Montreal to keep an eye on

      September 13, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»The Biotech Buying Bonanza: Why The FTC’s Amgen Battle Won’t Chill The Spree
    Bio Technology

    The Biotech Buying Bonanza: Why The FTC’s Amgen Battle Won’t Chill The Spree

    yourbiotechBy yourbiotechJune 5, 2023Updated:June 5, 2023No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Big Pharma has a problem, and a plan to solve it. The problem? A looming drug patent cliff that will unleash generic competition on some of the industry’s biggest moneymakers. The solution? A breakneck M&A spree for biotech stocks, funded by a massive war chest built on drug companies’ success in bringing new medical treatments to market.

    But U.S. regulators could throw a wrench into this biotech M&A game plan. The Federal Trade Commission filed a lawsuit May 16 to block Amgen’s $27.8 billion takeover of Horizon Therapeutics (HZNP). The challenge raised new arguments against such mergers, which the FTC routinely cleared in the past when the companies had no rival drugs on the market.

    Analysts expect Amgen (AMGN) will eventually close the Horizon buyout, but it may face an uphill court battle to get there. At risk are drug companies’ plans to head off revenue hits as important patents expire and a government drug-price squeeze looms.

    The stakes also are high for biotech stocks and investors who own them. Many companies never turn a profit and lack the business wherewithal to market their products. They capitalize on their R&D successes by selling out to bigger companies.

    ‘Blistering’ M&A Pace

    As of mid-April, pharma companies had announced $64 billion in biotech mergers and acquisitions this year, with big names like Pfizer (PFE) and Merck (MRK) on the list of shoppers. That put biotech on a “blistering” M&A pace in 2023, according to investment bank Torreya, now a Stifel unit.

    The Amgen-Horizon roadblock from President Biden’s FTC reverberated across the industry, as biotech stocks pulled back from a recent run. Shares of takeover targets Seagen (SGEN) and Prometheus Biosciences (RXDX) fell 6% and 1%, respectively, the day of the FTC action. As of Thursday though, biotech stocks ranked a lofty 11th in six-month price performance among 197 industry groups tracked by Investor’s Business Daily.

    Despite regulators’ chilly tone, some experts don’t expect a pause in the M&A pace for biotech stocks.

    Biotech stocks M&A deals chart


    The macroeconomic environment, politics, drug prices, patent cliffs and regulatory concerns are in constant flux. What doesn’t change? Biotech and pharma need each other.

    Biotech companies are often at the bleeding edge of innovation. But they lack the commercial power that pharmaceutical companies can bring to the table.

    “It doesn’t really change the game of where pharma is going to acquire,” said Stephen Morehouse, a partner at PA Consulting, where he advises life-sciences companies. “They need to. It’s part of how the industry works. There’s innovation going on, and they’re going to acquire that innovation or seek other opportunities to continue to grow and find new treatments.”

    Several factors are driving the biotech M&A spree, experts say, and much of the frenzy dates back to early days of the pandemic.

    Valuations Of Biotech Stocks

    Biotech stocks took off in 2020 as the world looked to companies like Pfizer and Moderna (MRNA) for new vaccine technology to save the world. Then, Covid-19 cases began to ease. And society peeled back many of the measures meant to keep the virus at bay.

    Big Pharma may have been waiting for promising clinical news before jumping on the M&A bandwagon.

    “There had been such a dramatic shift in valuations,” said Adam Golden, a partner at the law firm Freshfields Bruckhaus Deringer who helps life sciences companies ink mergers, licensing deals and collaborations. “I think it took a little bit longer for buyers and sellers to kind of adjust to the new world in terms of valuations.”

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleChina reaching for biotech breakthroughs in space
    Next Article Biotechs face challenges as the industry’s annual bash returns to Boston
    yourbiotech
    • Website

    Related Posts

    Liftoff for the Biotech Launch Pad

    September 20, 2023

    Five things: A biotech IPO, Shannon O’Brien suspension, life sciences philanthropy report

    September 19, 2023

    Machine learning biotech raises $273 million in rare successful late-stage round

    September 15, 2023

    Discover the synergy between biotech, medtech and digital health in Ghent, a European technology capital

    September 14, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.